Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IQ Healthy Hearts ETF HART

The Fund seeks investment results that correspond (before fees and expenses) generally to the price and yield performance of its underlying index, the IQ Candriam Healthy Hearts Index The Fund employs a passive management ¿ or indexing ¿ investment approach designed to track the performance of the Underlying Index, which was developed by IndexIQ LLC


ARCA:HART - Post by User

IQ Healthy Hearts ETF
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(902)
•••
Post by CommonCentsforDollarson Nov 28, 2014 3:12pm
220 Views
Post# 23175206

Harvard Apparatus Regenerative Technology No Longer Supporti

Harvard Apparatus Regenerative Technology No Longer Supporti

Harvard Apparatus Regenerative Technology No Longer Supporting Studies in Russia; Will Continue Focus on Preclinical Processes in the U.S. and EU


https://investor.harvardapparatusregen.com/press-release/harvard-apparatus-regenerative-technology-no-longer-supporting-studies-russia-will-con
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities